HER2 status in bilateral breast cancer.
BACKGROUND
The purpose of this study was to identify correlates of HER2 status for patients with bilateral breast cancer.


METHODS
Data were collected prospectively in our institutional review board approved patient registry for all patients with asynchronous (ABBC) and synchronous (SBBC) bilateral infiltrating breast cancer whose HER2 assays were performed at our laboratory using FISH. Data were analyzed using the Wilcoxon rank sum and Chi-square test.


RESULTS
Data were available for 98 tumors in 49 patients. Patients diagnosed with SBBC were more likely to be white (P = 0.023); to have bilateral HER2 non-amplified tumors (P = 0.022) and to be older at diagnosis (P = 0.025) compared to those with ABBC. Patients with one HER2 amplified tumor were likely to have at least one tumor be hormone receptor negative and to have ABBC.


CONCLUSIONS
Only 16% of patients in this study had one tumor that was HER2 amplified; no patient had bilateral HER2 amplified tumors.
Crowe
Joseph P
JP
Departments of General Surgery-Breast Center, The Cleveland Clinic, Cleveland, Ohio 44195, USA. crowej@ccf.org
Patrick
Rebecca J
RJ
Rybicki
Lisa A
LA
Budd
G Thomas
GT
Escobar
Pedro F
PF
Tubbs
Raymond R
RR
Hicks
David G
DG
D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000235:genetics*; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D008499:Medical Records / Q000706:statistics & numerical data; D009361:Neoplasm Invasiveness; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D014481:United States / Q000453:epidemiology; D016387:Women's Health
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases